Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Spray Clear all
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

NCT00763555
View directory record Official record
Conditions
Psoriasis
Interventions
CD 2027, Calcitriol Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Fridley, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Not listed Phase 3 Interventional

TDT 067 Onychomycosis Study

NCT01145807
View directory record Official record
Conditions
Onychomycosis
Interventions
TDT067, Placebo, Transfersome
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years to 75 Years
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Albequerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

NCT05161208
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 18, 2026, 2:41 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

NCT00716807
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
Interventions
nalbuphine plus naloxone, nalbuphine plus placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

NCT03488563
View directory record Official record
Conditions
Migraine
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
22
States / cities
Little Rock, Arkansas • Long Beach, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

NCT03290248
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
Interventions
B244 suspension, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 18, 2026, 2:41 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.

NCT07599800
View directory record Official record
Conditions
PHN - Post-Herpetic Neuritis
Interventions
APC101, Control
Drug · Other
Lead sponsor
Andros Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Florida City, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Alleviation of Common Cold Symptoms

NCT06106880
View directory record Official record
Conditions
Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions
Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet
Drug · Dietary Supplement · Other
Lead sponsor
Applied Biological Laboratories Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT04036292
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis

NCT01947491
View directory record Official record
Conditions
Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion, Vehicle Lotion, Vehicle Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Encinitas, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

NCT01018134
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily, Vehicle once daily, Vehicle twice daily
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Miami, Florida • Martinez, Georgia • Olathe, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults

NCT05114486
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic administered with the Optejet dispenser, Placebo administered with the Optejet dispenser
Combination Product
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 55 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
San Diego, California • Fairfield, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Determine if Fibrin Affects the Ability of a Wound to Heal

NCT01253135
View directory record Official record
Conditions
Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Interventions
Fibrin, White Petrolatum
Biological · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers

NCT02908620
View directory record Official record
Conditions
Anesthesia
Interventions
One spray CTY-5339-A, One spray CTY-5339-CB, Two sprays CTY-5339-A, One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)
Combination Product · Drug
Lead sponsor
Cetylite Industries
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

NCT01817790
View directory record Official record
Conditions
Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 18, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis

NCT02025751
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 18, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 18, 2026, 2:41 PM EDT